mov018-Fc-GrB

mov018-Fc-GrB (also referred to as GrB-Fc-mov018) is an experimental, first-in-class recombinant fusion protein immunotoxin being developed for the treatment of Folate Receptor alpha (FRα)-expressing cancers, including ovarian cancer, breast cancer, and acute myeloid leukemia (AML). The therapeutic consists of a human single-chain variable fragment (scFv) derived from the mov018 antibody, which specifically targets FRα (FOLR1), fused to an active human granzyme B (GrB) payload via a human IgG Fc dimerization domain. Upon binding to FRα on the tumor cell surface, the construct is internalized, delivering the pro-apoptotic serine protease granzyme B into the cytosol. Once in the cytosol, granzyme B triggers the apoptotic cascade, effectively bypassing common resistance mechanisms such as those associated with Bcl-2 inhibition (e.g., Venetoclax resistance). Developed primarily at the MD Anderson Cancer Center, this agent represents a novel approach to targeted protein delivery for chemo-resistant solid and liquid tumors.

Other names

Granzyme B-Fc-Anti-FRA fusion proteinGrB-Fc-mov018GrB-Fc-mov-018GrB-Fc-mov 018